Aurinia Pharmaceuticals to Release Fourth Quarter and Year End 2020 Financial Results on February 24, 2021
February 17 2021 - 6:05AM
Business Wire
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the
“Company”) today announced that it will release its fourth quarter
and year end 2020 financial results on Wednesday, February 24,
2021, after the markets close. Aurinia’s management team will host
a conference call to discuss the Company’s financial results and to
provide a general business update.
The conference call and webcast is scheduled for February 24,
2021 at 4:30pm ET. In order to participate in the conference call,
please dial +1-877-407-9170 (Toll-free U.S. & Canada). An audio
webcast can be accessed under "News/Events” through the “Investors”
section of the Aurinia corporate website at www.auriniapharma.com.
A replay of the webcast will be available on Aurinia’s website.
ABOUT AURINIA
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical
company focused on delivering therapies to treat targeted patient
populations that are impacted by serious diseases with a high unmet
medical need. The Company has introduced LUPKYNIS™ (voclosporin),
the first FDA-approved oral therapy dedicated for the treatment of
adult patients with active lupus nephritis (LN). The Company’s head
office is in Victoria, British Columbia, its U.S. commercial hub is
in Rockville, Maryland, and the Company focuses its development
efforts globally.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210217005243/en/
Investor Contact: Glenn Schulman, PharmD, MPH SVP,
Corporate Communications & IR gschulman@auriniapharma.com
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From Apr 2024 to May 2024
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From May 2023 to May 2024